IL6 and Fever: Notably, AE incidence and severity (rash, hypotension, pruritus, and pyrexia) declined on continued dosing, no anti-IL-6 therapy was required, and no treatment-related deaths occurred, underscoring a predictable, front-loaded but controllable safety profile for tebentafusp.